BRPI0406667A - Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg - Google Patents

Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg

Info

Publication number
BRPI0406667A
BRPI0406667A BR0406667-7A BRPI0406667A BRPI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A BR PI0406667 A BRPI0406667 A BR PI0406667A
Authority
BR
Brazil
Prior art keywords
acceptable formulation
treating cancer
therapeutically acceptable
cancer
administered
Prior art date
Application number
BR0406667-7A
Other languages
English (en)
Inventor
George Tidmarsh
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of BRPI0406667A publication Critical patent/BRPI0406667A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"MéTODO PARA O TRATAMENTO DE CâNCER, E, FORMULAçãO TERAPEUTICAMENTE ACEITáVEL DE 2-DG". O composto 2-desoxiglicose pode ser usado para tratar câncer e para melhorar o resultado do paciente, quando administrado em uma dose terapeuticamente eficaz, e, opcionalmente, co-administrado com outras drogas anti-câncer, ou em continuação com resseção cirúrgica ou terapia de radiação.
BR0406667-7A 2003-01-10 2004-01-09 Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg BRPI0406667A (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US43926603P 2003-01-10 2003-01-10
US45866503P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US46001203P 2003-04-02 2003-04-02
US49616303P 2003-08-18 2003-08-18
PCT/US2004/000530 WO2004062604A2 (en) 2003-01-10 2004-01-09 Treatment of cancer with 2-deoxyglucose

Publications (1)

Publication Number Publication Date
BRPI0406667A true BRPI0406667A (pt) 2005-12-20

Family

ID=32719656

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0406667-7A BRPI0406667A (pt) 2003-01-10 2004-01-09 Método para o tratamento de câncer, e, formulação terapeuticamente aceitável de 2-dg

Country Status (11)

Country Link
US (2) US6979675B2 (pt)
EP (1) EP1587519A4 (pt)
JP (1) JP2006515883A (pt)
KR (1) KR20050098244A (pt)
AU (1) AU2004204778B2 (pt)
BR (1) BRPI0406667A (pt)
CA (1) CA2513399A1 (pt)
IL (1) IL169594A0 (pt)
MX (1) MXPA05007382A (pt)
NO (1) NO20053782L (pt)
WO (1) WO2004062604A2 (pt)

Families Citing this family (118)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563522B2 (en) 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US7381413B1 (en) * 1998-04-17 2008-06-03 University Of Vermont And State Agricultural College Methods and products related to metabolic interactions in disease
EP1205493A1 (en) * 2000-11-14 2002-05-15 ATOFINA Research Polymerisation catalyst systems and their preparation
US7666459B2 (en) * 2001-09-12 2010-02-23 The Procter & Gamble Company Pet food compositions
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
EP1599196A4 (en) * 2003-01-17 2006-05-31 Threshold Pharmaceuticals Inc COMBINATION THERAPIES FOR CANCER TREATMENT
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
WO2005070126A2 (en) * 2004-01-08 2005-08-04 The Regents Of The University Of Colorado Methods and compositions for treating human diseases and wounds with ucp and fas inhibitors
KR20120117943A (ko) 2004-02-06 2012-10-24 쓰레솔드 파마슈티컬스, 인코포레이티드 항암 치료 방법
US20090252834A1 (en) * 2004-05-10 2009-10-08 Michael Griffin Hayek Compositions comprising glucose anti-metabolites
JP2008502705A (ja) * 2004-06-17 2008-01-31 ウィスコンシン・アルムニ・リサーチ・ファウンデーション 発作および発作性障害を処置するための化合物ならびに方法
WO2006024488A2 (en) * 2004-08-30 2006-03-09 Interstitial Therapeutics Medical stent provided with inhibitors of atp synthesis
US20060078580A1 (en) * 2004-10-08 2006-04-13 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
US7740875B2 (en) * 2004-10-08 2010-06-22 Mediquest Therapeutics, Inc. Organo-gel formulations for therapeutic applications
BRPI0517268A (pt) * 2004-11-02 2008-10-07 Conforma Therapeutics Corp método para tratar uma forma de leucemia linfocìtica crÈnica
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
WO2006108681A2 (en) 2005-04-15 2006-10-19 Biomac Privatinstitut Für Medizinische Und Zahnmedizinische Forschung, Entwicklung Und Diagnostik Gmbh Substances and pharmaceutical compositions for the inhibition of glyoxalases and their use against bacteria
JP4938006B2 (ja) 2005-05-31 2012-05-23 ザ・アイムス・カンパニー ネコ科動物プロバイオティク・ビフィドバクテリア
EP2261323A1 (en) 2005-05-31 2010-12-15 The Iams Company Feline probiotic lactobacilli
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
WO2006137595A1 (ja) * 2005-06-24 2006-12-28 Takeda Pharmaceutical Company Limited Ｈｅｒ２発現癌の予防・治療薬
US20070032383A1 (en) * 2005-07-27 2007-02-08 Newell M K Systems, methods, and compositions for modifying the metabolism of plants and of euucaryotic microbes
US20070134349A1 (en) * 2005-09-19 2007-06-14 Duke University Methods of treating hematological malignancies
US8278349B2 (en) 2005-11-28 2012-10-02 Ramot At Tel-Aviv University Ltd. Cancer treatment using FTS and 2-deoxyglucose
WO2007067516A2 (en) * 2005-12-06 2007-06-14 Duke University Multiple myeloma
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
US7754693B2 (en) * 2006-02-16 2010-07-13 Young Hee Ko Composition and method for the efficacious and safe administration of halopyruvate for the treatment of cancer
EP1986660A4 (en) * 2006-02-24 2009-08-26 Univ Texas HEXOSE COMPOUNDS FOR CANCER TREATMENT
CN101426508A (zh) * 2006-02-24 2009-05-06 得克萨斯系统大学评议会 治疗癌症的己糖化合物
US9149489B2 (en) * 2006-04-27 2015-10-06 Board Of Regents, University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
WO2009108926A1 (en) * 2008-02-29 2009-09-03 Board Of Regents, The University Of Texas System Inhibitors of glycolysis useful in the treatment of brain tumors
AU2007246077A1 (en) * 2006-05-03 2007-11-08 I.Q.A., A.S. Pharmaceutical composition containing taxane derivative destined for the preparation of an infusion solution, method of preparation thereof and use thereof
EP2161332B1 (en) 2006-11-20 2015-04-22 National University Corporation Kagawa University Deoxyketohexose isomerase and method for producing deoxyhexose and derivative thereof using same
EP2114413B1 (en) * 2006-12-18 2014-10-22 The Johns Hopkins University Therapeutics for treating cancer using 3-bromopyruvate
WO2008093303A2 (en) 2007-02-01 2008-08-07 The Iams Company Method for decreasing inflammation and stress in a mammal using glucose antimetaboltes, avocado or avocado extracts
EP2156188B1 (en) 2007-03-28 2021-05-05 University of Southern California Induction of differential stress resistance and uses thereof
US8865646B2 (en) * 2007-03-28 2014-10-21 University Of South California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
RU2349271C2 (ru) * 2007-03-29 2009-03-20 ФГУ Ростовский научно-исследовательский онкологический институт Росздрава Способ лечения рака прямой кишки
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
US8765690B2 (en) * 2007-04-05 2014-07-01 Threshold Pharmaceuticals, Inc. Treatment of cancer with glufosfamide in patients not receiving insulin therapy
US20110091574A1 (en) * 2008-02-15 2011-04-21 Catholic Healthcare West Treatment of adenocarcinoma expressing lkb1 with mtor inhibitor in combination with cox2 inhibitor
CA2716321A1 (en) 2008-02-21 2009-08-27 The Regents Of The University Of Colorado Methods for treating cancer using combination therapy
PL2282773T3 (pl) 2008-05-02 2014-08-29 Seattle Genetics Inc Sposoby i kompozycje do wytwarzania przeciwciał i pochodnych przeciwciał o obniżonej fukozylacji rdzeniowej
US20110183926A1 (en) * 2008-05-23 2011-07-28 University Of Miami Treatment using continuous low dose application of sugar analogs
TW200950777A (en) * 2008-05-27 2009-12-16 Oncolytics Biotech Inc Abrogating proinflammatory cytokine production during oncolytic reovirus therapy
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US8927506B2 (en) * 2008-07-11 2015-01-06 Board Of Regents, The University Of Texas System Acetates of 2-deoxy monosaccharides with anticancer activity
US9073985B2 (en) 2008-07-14 2015-07-07 The Regents Of The University Of Colorado, A Body Corporate Methods and products for treating proliferative diseases
US20110207680A1 (en) * 2008-08-13 2011-08-25 Curd John G Administration of Glufosfamide For The Treatment of Cancer
WO2010021750A2 (en) * 2008-08-21 2010-02-25 The Johns Hopkins University Methods and compositions for administration of 3-halopyruvate and related compounds for the treatment of cancer
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
NZ594434A (en) * 2009-01-29 2014-11-28 Young Hee Ko Compositions and methods for the treatment of cancer
CN102985557B (zh) 2009-03-13 2018-06-15 安吉奥斯医药品有限公司 用于细胞增殖相关病症的方法和组合物
PE20120693A1 (es) 2009-06-29 2012-07-04 Agios Pharmaceuticals Inc Compuestos heterociclos como moduladores de la piruvato cinasa m2 (pkm2)
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8450090B2 (en) 2009-10-06 2013-05-28 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for promoting fatty acid production in plants
EP2525790B1 (en) 2009-10-21 2020-05-27 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
WO2011050210A1 (en) * 2009-10-21 2011-04-28 Agios Pharmaceuticals, Inc. Methods and compositions for cell-proliferation-related disorders
SG10201406651PA (en) * 2009-10-22 2014-11-27 Propanc Pty Ltd A pharmaceutical composition for treating cancer comprising trypsinogen and/orchymotrypsinogen and an active agent selected from a selenium compound, a vanilloid compoundand a cytoplasmic glycolysis reduction agent
CN102115483B (zh) * 2009-12-30 2014-12-17 苏州天人合生物技术有限公司 卤代双去氧糖衍生物及其制备方法与应用
GB2478556A (en) * 2010-03-09 2011-09-14 Myrovlytis Technology Ventures Ltd A composition for use in the treatment of Birt-Hogg-Dubô sydrome
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
EP3513794A3 (en) 2010-08-05 2019-10-16 Seattle Genetics, Inc. Fucose analogs for inhibition of protein fucosylation in vivo
WO2012049439A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis
WO2012049440A1 (en) * 2010-10-13 2012-04-19 Imperial Innovations Limited Treatment of cancer/inhibition of metastasis
WO2012097052A2 (en) * 2011-01-11 2012-07-19 Intertech Bio, Llc Monosaccharide-based compounds for the treatment of proliferative and inflammatory dermatological diseases
WO2012123774A1 (en) * 2011-03-11 2012-09-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Glycolytic inhibitor with cytotoxic agent for use in the treatment of a cancer
US20120238511A1 (en) * 2011-03-14 2012-09-20 University Of Southern California 2-deoxy-d-glucose formulations for prevention or treatment of neurodegenerative diseases
PT3406251T (pt) 2011-05-03 2024-01-24 Agios Pharmaceuticals Inc Ativadores da piruvato-cinase para utilização em terapia
CN102827170A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
CN102827073A (zh) 2011-06-17 2012-12-19 安吉奥斯医药品有限公司 治疗活性组合物和它们的使用方法
US20130196349A1 (en) * 2011-08-02 2013-08-01 Realbio Technology, Inc. In Vitro Tumor Metastasis Model
KR101900478B1 (ko) * 2011-08-04 2018-09-20 한올바이오파마주식회사 암의 재발 또는 전이의 억제용 약제학적 조성물
SMT201800334T1 (it) 2012-01-06 2018-09-13 Agios Pharmaceuticals Inc Composti terapeuticamente attivi e loro metodi di utilizzo
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
US20160015725A1 (en) * 2012-02-14 2016-01-21 The Wistar Institute Of Anatomy And Biology Methods of controlling tumor bioenergetics networks
AU2013202693B2 (en) * 2012-04-16 2015-01-22 Baxalta GmbH Combination Therapy of Anti-MIF Antibodies and Chemotherapeutics
EP2887947B1 (en) 2012-08-23 2019-06-05 Seattle Genetics, Inc. Fucose analogues for the treatment of sickle cell disease
WO2014062511A1 (en) 2012-10-15 2014-04-24 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
WO2014072967A1 (en) * 2012-11-12 2014-05-15 Urifer Ltd Drug combination comprising a glycolysis inhibitor and a tyrosine kinase inhibitor
KR101419816B1 (ko) * 2013-01-30 2014-07-17 (주)제욱 상승적 치료 효과를 갖는 비소세포폐암의 예방 또는 치료용 조성물
ES2897699T3 (es) 2013-04-05 2022-03-02 Univ Texas Esteres de 2-desoxi-monosacáridos con actividad antiproliferativa
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CN105593215B (zh) 2013-07-11 2019-01-15 安吉奥斯医药品有限公司 用于治疗癌症的作为idh2突变体抑制剂的2,4-或4,6-二氨基嘧啶化合物
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015010297A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
CA2936940C (en) 2014-01-14 2023-07-04 The Johns Hopkins University Cyclodextrin compositions encapsulating a selective atp inhibitor and uses thereof
PH12021551647A1 (en) 2014-03-14 2022-06-06 Agios Pharmaceuticals Inc Pharmaceutical compositions of therapeutically active compounds
WO2016065353A1 (en) * 2014-10-24 2016-04-28 University Of Miami Combination therapy with fenofibrate and 2-deoxyglucose or 2-deoxymannose
MX384883B (es) 2015-06-11 2025-03-14 Agios Pharmaceuticals Inc Métodos para usar activadores de piruvato cinasa.
HUE067449T2 (hu) 2015-10-15 2024-10-28 Servier Lab Ivozidenib, citarabin és daunorubicin vagy idarubicin kombinációs terápa akut mielogén leukémia kezelésére
MD3362066T2 (ro) 2015-10-15 2022-08-31 Les Laboratoires Servier Sas Terapie combinată pentru tratamentul tumorilor maligne
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
HK1259489A1 (zh) 2015-11-12 2019-11-29 普罗潘克股份有限公司 酶原组合物
CN108697771A (zh) 2016-01-29 2018-10-23 普罗潘克股份有限公司 癌症治疗
WO2017173360A2 (en) * 2016-03-31 2017-10-05 Stcube, Inc. Combination treatments directed toward programmed death ligand-1 (pd-l1) positive cancers
JP6888239B2 (ja) 2017-06-28 2021-06-16 株式会社 ＳＥＮＴＡＮ Ｐｈａｒｍａ 腫瘍治療用腫瘍免疫活性促進剤及び腫瘍治療用医薬組成物
BR112020001285A2 (pt) 2017-07-21 2020-07-28 Buck Institute For Research On Aging s-enantiômeros de beta-hidroxibutirato e butanodiol e métodos para sua utilização
US12037317B2 (en) 2018-01-25 2024-07-16 Buck Institute For Research On Aging Synthesis of 3-hydroxybutyryl 3-hydroxybutyrate and related compounds
SMT202300073T1 (it) 2018-05-16 2023-05-12 Forma Therapeutics Inc Inibizione di idh-1 mutante
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
WO2019222551A1 (en) 2018-05-16 2019-11-21 Forma Therapeutics, Inc. Solid forms of ((s)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
RU2707554C1 (ru) * 2019-02-27 2019-11-28 Федеральное государственное бюджетное учреждение "Петербургский институт ядерной физики им. Б.П. Константинова Национального исследовательского центра "Курчатовский институт" (НИЦ "Курчатовский институт-ПИЯФ") Композиция, ингибирующая рост и выживаемость опухолевых клеток
IL296389A (en) 2020-03-16 2022-11-01 Univ Texas Method of treating viral infections with hexose type monosaccharides and analogs thereof
WO2021211609A1 (en) * 2020-04-16 2021-10-21 Buck Institute For Research On Aging Treatment of viral pathologies with exogenous ketones
CA3200999A1 (en) * 2020-12-14 2022-06-23 Miguel Angel Barajas Velez Compositions comprising bacteria for cancer immunotherapy
WO2023062516A1 (en) * 2021-10-11 2023-04-20 Exploration Invest Pte Ltd 2-deoxy-d-glucose for use in disease therapy
CN114617876B (zh) * 2022-01-28 2023-04-07 四川大学华西医院 一种抗肿瘤联合用药物
KR102980182B1 (ko) 2022-09-16 2026-06-19 이화여자대학교 산학협력단 해당과정 억제제 및 미토콘드리아 기능 억제제를 포함하는 암의 예방 또는 치료용 약학적 조성물
EP4582080A1 (en) 2024-01-02 2025-07-09 G.ST Antivirals GmbH Dispenser for mucosal administration comprising 2-deoxy-glucose or analogues thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS606630B2 (ja) 1977-09-07 1985-02-19 藤沢薬品工業株式会社 ２―デオキシ―ｄ―グルコースの製造法
US4315001A (en) * 1979-08-17 1982-02-09 Blough Herbert A 2-Deoxy glucose as an antiviral agent against herpes simplex
US5185325A (en) * 1988-06-23 1993-02-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Cosmetic composition
EP0565785A1 (en) 1992-04-07 1993-10-20 Harry H. Leveen Use of glucose transport inhibitors for the treatment for acne
KR950009111B1 (ko) * 1992-09-08 1995-08-14 주식회사럭키 광택 조절용 수지의 제조방법
US5591429A (en) * 1993-07-26 1997-01-07 The United States Of America As Represented By The Secretary Of Agriculture Composition containing 2-deoxy-D-glucose and Candida saitoana and a method of use for the biological control of postharvest diseases
US5643883A (en) * 1995-01-19 1997-07-01 Uab Research Foundation Glucose-6-phosphate uptake inhibitors and novel uses thereof
DE19524515A1 (de) * 1995-07-05 1997-01-09 Deutsches Krebsforsch Saccharid-Konjugate
US5652273A (en) * 1995-11-30 1997-07-29 Henry; James Reduction of hair growth
US5565434A (en) * 1996-02-23 1996-10-15 University Of Iowa Research Foundation Hexose and pentose prodrugs of ethacrynic acid
US5958892A (en) * 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
GR1003713B (el) 1998-03-20 2001-11-07 Δεσοξυσακχαρα ως αντικαρκινικοι αναχαιτιστικοι παραγοντες.
US20030072814A1 (en) * 1999-12-16 2003-04-17 Maibach Howard I. Topical pharmaceutical composition for the treatment of warts
US6670330B1 (en) * 2000-05-01 2003-12-30 Theodore J. Lampidis Cancer chemotherapy with 2-deoxy-D-glucose
US6974664B2 (en) * 2000-05-12 2005-12-13 The Board Of Trustees Of The Leland Stanford University Screening method for cancer therapeutics and stable antitumor drug
US20030021749A1 (en) 2000-12-18 2003-01-30 Yeung Alex Wah Hin Treatment of cancer and other diseases by administration of positron-emitting radiopharmaceuticals
US6661410B2 (en) * 2001-09-07 2003-12-09 Microsoft Corporation Capacitive sensing and data input device power management

Also Published As

Publication number Publication date
IL169594A0 (en) 2007-07-04
EP1587519A4 (en) 2006-05-31
MXPA05007382A (es) 2005-11-23
WO2004062604A2 (en) 2004-07-29
AU2004204778A1 (en) 2004-07-29
US20040167079A1 (en) 2004-08-26
NO20053782L (no) 2005-09-27
JP2006515883A (ja) 2006-06-08
AU2004204778B2 (en) 2008-05-22
WO2004062604A3 (en) 2005-05-26
US20050245462A1 (en) 2005-11-03
US6979675B2 (en) 2005-12-27
CA2513399A1 (en) 2004-07-29
NO20053782D0 (no) 2005-08-09
EP1587519A2 (en) 2005-10-26
KR20050098244A (ko) 2005-10-11

Similar Documents

Publication Publication Date Title
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
NO20014842L (no) Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft
Disa et al. Prevention of adriamycin-induced full-thickness skin loss using hyaluronidase infiltration
WO2004064734A3 (en) Combination therapies for the treatment of cancer
BR0113447A (pt) Método de tratamento ou prevenção do câncer em um ser humano, e, composição farmacêutica
BR0110877A (pt) Métodos de tratamento de câncer primário, de aumento da dosagem de um inibidor de topoisomerase, de redução ou prevenção de um efeito adverso associado com quimioterapia e com terapia de radiação, de aumento da eficácia terapêutica de um inibidor de topoisomerase, e de proteção de um paciente canceroso dos efeitos adversos associados com a administração de uma droga anti-câncer, composição farmacêutica, forma de dosagem, e, kit para uso no tratamento de câncer
BR9715022A (pt) Método para tratar de doenças prostáticas usando formulações de vitamina d por liberação sistemática e/ou prolongada
Loth et al. Treatment methods for extravasations of chemotherapeutic agents: a comparative study
WO2004039325A3 (en) Treatment of pain with jnk inhibitors
BR0116862A (pt) Medicamento, métodos para tratar um paciente com osteonecrose e/ou osteocondrite dissecans, para prevenir a osteonecrose e/ou osteocondrite dissecans em um paciente em risco de cada uma das ditas doenças, uso de um medicamento, e, método para prevenir a destruição da cartilagem ou condrólise associadas com osteonecrose e/ou osteocondrite dissecans
BRPI0413974A (pt) combinação, método de tratamento de cáncer em um animal de sangue quente, composição farmacêutica, e, uso de uma combinação
CY1107352T1 (el) Προεγχειρητικη θεραπευτικη αγωγη μετεγχειρητικου πονου
BRPI0413410A (pt) co-administração de um polissacarìdeo com um agente quimioterapêutico para o tratamento de cáncer
Maniar et al. Does postoperative intravenous ferric carboxymaltose hasten the recovery of hemoglobin in patients post total knee arthroplasty?
BR0314617A (pt) Método para cardioproteção e neuroproteção por administração intravenosa de anestésico voláteis halogenados
Schulmeister Totect™: A new agent for treating anthracycline extravasation
Cicchetti et al. Two case reports of vinorelbine extravasation: management and review of the literature
BR0315609A (pt) Método de tratar, prevenir, modificar ou controlar dor e composição farmacêutica
WO2001080895A3 (en) Methods and compositions for the treatment of cardiac indications
BRPI0412408A (pt) métodos para a produção de um efeito de redução antiangiogênico e/ou de permeabilidade vascular e para o tratamento de um cáncer em um animal de sangue quente tal como um ser humano, composição farmacêutica, kit, e uso de azd2171 ou um sal farmaceuticamente aceitável deste e zd1839 ou um sal farmaceuticamente aceitável deste
BRPI0416266A (pt) método para tratar, prevenir e/ou controlar uma doença ou distúrbio relacionada com amianto em um paciente
AU2001236529A1 (en) Combination therapy for cancer
ATE345805T1 (de) Calciumtrifluoracetat mit zytotoxischer wirkung
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.